Management of Childhood-onset Craniopharyngioma in Italy: A Multicenter, 7-Year Follow-up Study of 145 Patients.
Age of Onset
Child
Child, Preschool
Craniopharyngioma
/ complications
Female
Follow-Up Studies
Human Growth Hormone
/ therapeutic use
Humans
Hypophysectomy
/ adverse effects
Hypopituitarism
/ diagnosis
Italy
/ epidemiology
Male
Neoplasm, Residual
Pituitary Gland
/ pathology
Pituitary Neoplasms
/ complications
Postoperative Complications
/ epidemiology
Recurrence
Retrospective Studies
Treatment Outcome
GH therapy
children
craniopharyngioma
hypothalamic obesity
intracranial tumor
pituitary deficiency
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
17 02 2022
17 02 2022
Historique:
received:
18
06
2021
pubmed:
1
11
2021
medline:
3
3
2022
entrez:
31
10
2021
Statut:
ppublish
Résumé
Nationwide data on children diagnosed with craniopharyngioma (CP) are not available in Italy. This work aimed to identify patients' characteristics, type of surgical approach, complications and recurrences, number of pituitary deficits, and number of patients starting growth hormone (GH) treatment. A retrospective multicenter collection took place of 145 patients aged 0 to 18 years who underwent surgery for CP between 2000 and 2018, and followed up in 17 Italian centers of pediatric endocrinology. Age at diagnosis was 8.4 ± 4.1 years. Duration of symptoms was 10.8 ± 12.5 months and headache was most frequent (54%), followed by impaired growth (48%) and visual disturbances (44%). Most lesions were suprasellar (85%), and histology was adamantinomatous in all cases but two. Surgical approach was transcranial (TC) in 67.5% of cases and transsphenoidal (TS) in 31.%. The TC approach was prevalent in all age groups. Postsurgery complications occurred in 53% of cases, with water-electrolyte disturbances most frequent. Radiotherapy was used in 39% of cases. All patients but one presented with at least one hormone pituitary deficiency, with thyrotropin deficiency most frequent (98.3%), followed by adrenocorticotropin (96.8%), arginine vasopressin (91.1%), and GH (77.4%). Body mass index (BMI) significantly increased over time. A hypothalamic disturbance was present in 55% of cases. GH therapy was started during follow-up in 112 patients at a mean age of 10.6 years, and 54 developed a recurrence or regrowth of the residual lesion. CP is often diagnosed late in Italy, with TC more frequent than the TS surgical approach. Postsurgery complications were not rare, and hypopituitarism developed almost in all cases. BMI shows a tendency to increase overtime.
Identifiants
pubmed: 34718649
pii: 6414063
doi: 10.1210/clinem/dgab784
doi:
Substances chimiques
Human Growth Hormone
12629-01-5
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1020-e1031Investigateurs
Stefano Cianfarani
(S)
Mohamad Maghnie
(M)
Gerdi Tuli
(G)
Sandro Loche
(S)
Patrizia Bruzzi
(P)
Malgorzata Wasniewska
(M)
Mariacarolina Salerno
(M)
Irene Rutigliano
(I)
Maria Laura Iezzi
(ML)
Valentino Cherubini
(V)
Anna Grandone
(A)
Maria Felicia Faienza
(MF)
Stefano Tumini
(S)
Cristina Baldoli
(C)
Alessandro Consales
(A)
Lorenzo Genitori
(L)
Carlo Efisio Marras
(CE)
Claudia MIlanaccio
(C)
Pietro Mortini
(P)
Marco Vindigni
(M)
Francesco Zenga
(F)
Mino Zucchelli
(M)
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.